{"transactions":[{"id":940739,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-12T21:00:11.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":false,"shares":17666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date."}],"balance_after":35334,"derivative":{"underlying":"Common Stock","underlying_shares":17666},"source":{"system":"sec-edgar","filing":"0001193125-26-010865","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000119312526010865/ownership.xml","form_type":"4"}},{"id":940738,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-12T21:00:11.000Z","date":"2026-01-12","kind":"sale","planned":false,"acquired":false,"shares":9310,"price":22.6735,"value":211090.285,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory \"sell to cover\" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":26708,"source":{"system":"sec-edgar","filing":"0001193125-26-010865","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000119312526010865/ownership.xml","form_type":"4"}},{"id":940737,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-12T21:00:11.000Z","date":"2026-01-12","kind":"exercise","planned":false,"acquired":true,"shares":17666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon vesting of one third of the restricted stock units (\"RSUs\") granted on January 10, 2025."}],"balance_after":36018,"source":{"system":"sec-edgar","filing":"0001193125-26-010865","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000119312526010865/ownership.xml","form_type":"4"}},{"id":950012,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-05T20:22:16.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-003102","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000119312526003102/ownership.xml","form_type":"4"}},{"id":950011,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-05T20:22:16.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":10538,"price":25.0969,"value":264471.1322,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory \"sell to cover\" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.715 to $25.84, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":18352,"source":{"system":"sec-edgar","filing":"0001193125-26-003102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000119312526003102/ownership.xml","form_type":"4"}},{"id":950010,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-05T20:22:16.000Z","date":"2026-01-05","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon vesting of one third of the restricted stock units (\"RSUs\") granted on January 5, 2024."}],"balance_after":28890,"source":{"system":"sec-edgar","filing":"0001193125-26-003102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000119312526003102/ownership.xml","form_type":"4"}},{"id":1304883,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-10T18:03:11.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":53000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs vest in three equal annual installments beginning on first anniversary of grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs vest in three equal annual installments beginning on first anniversary of grant date."}],"balance_after":53000,"derivative":{"underlying":"Common Stock","underlying_shares":53000},"source":{"system":"sec-edgar","filing":"0000950170-25-004346","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000095017025004346/ownership.xml","form_type":"4"}},{"id":1304882,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-10T18:03:11.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":79000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date."}],"balance_after":79000,"derivative":{"exercise_price":13.22,"expiration_date":"2035-01-09","underlying":"Common Stock","underlying_shares":79000},"source":{"system":"sec-edgar","filing":"0000950170-25-004346","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000095017025004346/ownership.xml","form_type":"4"}},{"id":1309719,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-06T20:19:27.000Z","date":"2025-01-06","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024."}],"balance_after":40000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-002490","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000095017025002490/ownership.xml","form_type":"4"}},{"id":1309718,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-06T20:19:27.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":11110,"price":14.9241,"value":165806.751,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory \"sell to cover\" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.44 to $15.14, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":8890,"source":{"system":"sec-edgar","filing":"0000950170-25-002490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000095017025002490/ownership.xml","form_type":"4"}},{"id":1309717,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-06T20:19:27.000Z","date":"2025-01-06","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock issued upon vesting of one third of the restricted stock units (\"RSUs\") granted on January 5, 2024."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0000950170-25-002490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000095017025002490/ownership.xml","form_type":"4"}},{"id":1683692,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-08T18:00:33.000Z","date":"2024-01-05","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in three equal annual installments beginning on January 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in three equal annual installments beginning on January 5, 2025."}],"balance_after":60000,"derivative":{"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-003065","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000095017024003065/ownership.xml","form_type":"4"}},{"id":1683691,"issuer":{"id":4458,"kind":"organization","name":"Zymeworks Inc.","symbol":"ZYME"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-08T18:00:33.000Z","date":"2024-01-05","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date."}],"balance_after":90000,"derivative":{"exercise_price":10.56,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000950170-24-003065","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604800/000095017024003065/ownership.xml","form_type":"4"}},{"id":3388704,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the \"2019 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":14,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388703,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the \"2018 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":13.55,"expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388702,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the \"December 2017 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the December 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the December 2017 Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":10.7,"expiration_date":"2027-12-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388701,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the \"2017 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2017 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2017 Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":20.4,"expiration_date":"2027-01-26","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388700,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2016 (the \"2016 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2016 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2016 Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":24.18,"expiration_date":"2026-01-28","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388699,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2015 (the \"2015 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2015 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2015 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":28.23,"expiration_date":"2025-01-25","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388698,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of July 8, 2014 (the \"July 2014 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the July 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the July 2014 Vesting Commencement Date.  The shares subject to this option are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":16.9,"expiration_date":"2024-07-07","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388697,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":13636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of May 7, 2014 (the \"May 2014 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the May 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the May 2014 Vesting Commencement Date.  The shares subject to this option are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":10,"expiration_date":"2024-05-06","underlying":"Common Stock","underlying_shares":13636},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388696,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":13636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2014 (the \"2014 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2014 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2014 Vesting Commencement Date.  The shares subject to this option are fully vested as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":6.765,"expiration_date":"2024-02-10","underlying":"Common Stock","underlying_shares":13636},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388695,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":31818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."}],"balance_after":0,"derivative":{"exercise_price":3.465,"expiration_date":"2022-12-11","underlying":"Common Stock","underlying_shares":31818},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388694,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":17271,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."}],"balance_after":0,"derivative":{"exercise_price":3.465,"expiration_date":"2022-06-12","underlying":"Common Stock","underlying_shares":17271},"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388693,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":21502,"price":18,"value":387036.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC and Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\").  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3388692,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2019-10-24T19:07:40.000Z","date":"2019-10-22","kind":"grant","acquired":true,"shares":16230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 25,518 shares of Issuer's Common Stock (the \"RSU\"), of which 9,288 shares had vested and the remaining 16,230 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer.  The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 2)."}],"balance_after":21502,"source":{"system":"sec-edgar","filing":"0001209191-19-053919","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119053919/doc4.xml","form_type":"4"}},{"id":3410753,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-18T16:45:28.000Z","date":"2019-09-16","kind":"exercise","acquired":false,"shares":10001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."}],"balance_after":17271,"derivative":{"exercise_price":3.465,"expiration_date":"2022-06-12","underlying":"Common Stock","underlying_shares":10001},"source":{"system":"sec-edgar","filing":"0001209191-19-050079","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119050079/doc4.xml","form_type":"4"}},{"id":3410752,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-09-18T16:45:28.000Z","date":"2019-09-16","kind":"exercise","acquired":false,"shares":22727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.455,"expiration_date":"2020-02-25","underlying":"Common Stock","underlying_shares":22727},"source":{"system":"sec-edgar","filing":"0001209191-19-050079","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119050079/doc4.xml","form_type":"4"}},{"id":3410751,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2019-09-18T16:45:28.000Z","date":"2019-09-16","kind":"sale","acquired":false,"shares":32728,"price":18.44,"value":603504.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.355 to $18.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":5272,"source":{"system":"sec-edgar","filing":"0001209191-19-050079","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119050079/doc4.xml","form_type":"4"}},{"id":3410750,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2019-09-18T16:45:28.000Z","date":"2019-09-16","kind":"exercise","acquired":true,"shares":10001,"price":3.465,"value":34653.465,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2019."}],"balance_after":38000,"source":{"system":"sec-edgar","filing":"0001209191-19-050079","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119050079/doc4.xml","form_type":"4"}},{"id":3410749,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2019-09-18T16:45:28.000Z","date":"2019-09-16","kind":"exercise","acquired":true,"shares":22727,"price":4.455,"value":101248.785,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2019."}],"balance_after":27999,"source":{"system":"sec-edgar","filing":"0001209191-19-050079","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119050079/doc4.xml","form_type":"4"}},{"id":3548631,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2019-04-25T18:51:46.000Z","date":"2019-04-25","kind":"disposition_to_issuer","acquired":false,"shares":4847,"price":13.7251,"value":66525.5597,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSU.  The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.721 to $13.8695, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":5272,"source":{"system":"sec-edgar","filing":"0001209191-19-026035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119026035/doc4.xml","form_type":"4"}},{"id":3548630,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2019-04-25T18:51:46.000Z","date":"2019-04-23","kind":"grant","acquired":true,"shares":9288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On January 2, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 27,865 shares of Issuer's Common Stock (the \"RSU\"). Up to 9,288 shares subject to the RSU vest upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the \"FDA\") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the \"FDA Filing Milestone\") and the remaining shares subject to the RSU vest upon certain other performance criteria. On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 9,288 shares subject to the RSU."}],"balance_after":10119,"source":{"system":"sec-edgar","filing":"0001209191-19-026035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119026035/doc4.xml","form_type":"4"}},{"id":3667958,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T16:52:45.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":100000,"derivative":{"exercise_price":14,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-008595","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919119008595/doc4.xml","form_type":"4"}},{"id":3743517,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-04T18:39:08.000Z","date":"2018-12-03","kind":"exercise","acquired":false,"shares":5044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.99,"expiration_date":"2019-04-20","underlying":"Common Stock","underlying_shares":5044},"source":{"system":"sec-edgar","filing":"0001209191-18-061036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118061036/doc4.xml","form_type":"4"}},{"id":3743516,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-12-04T18:39:08.000Z","date":"2018-12-03","kind":"sale","acquired":false,"shares":5044,"price":13.8434,"value":69826.1096,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.59 to $14.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":831,"source":{"system":"sec-edgar","filing":"0001209191-18-061036","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118061036/doc4.xml","form_type":"4"}},{"id":3743515,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-12-04T18:39:08.000Z","date":"2018-12-03","kind":"exercise","acquired":true,"shares":5044,"price":0.99,"value":4993.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":5875,"source":{"system":"sec-edgar","filing":"0001209191-18-061036","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118061036/doc4.xml","form_type":"4"}},{"id":3774047,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-05T17:47:54.000Z","date":"2018-11-01","kind":"exercise","acquired":false,"shares":5040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."}],"balance_after":5044,"derivative":{"exercise_price":0.99,"expiration_date":"2019-04-20","underlying":"Common Stock","underlying_shares":5040},"source":{"system":"sec-edgar","filing":"0001209191-18-057264","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118057264/doc4.xml","form_type":"4"}},{"id":3774046,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-11-05T17:47:54.000Z","date":"2018-11-01","kind":"sale","acquired":false,"shares":5040,"price":13.42,"value":67636.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":831,"source":{"system":"sec-edgar","filing":"0001209191-18-057264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118057264/doc4.xml","form_type":"4"}},{"id":3774045,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-11-05T17:47:54.000Z","date":"2018-11-01","kind":"exercise","acquired":true,"shares":5040,"price":0.99,"value":4989.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":5871,"source":{"system":"sec-edgar","filing":"0001209191-18-057264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118057264/doc4.xml","form_type":"4"}},{"id":3798490,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-03T18:33:25.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":5040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this stock option are fully vested."}],"balance_after":10084,"derivative":{"exercise_price":0.99,"expiration_date":"2019-04-20","underlying":"Common Stock","underlying_shares":5040},"source":{"system":"sec-edgar","filing":"0001209191-18-054090","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118054090/doc4.xml","form_type":"4"}},{"id":3798489,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-10-03T18:33:25.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":2000,"price":15.9721,"value":31944.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.76 to $16.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4."}],"balance_after":831,"source":{"system":"sec-edgar","filing":"0001209191-18-054090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118054090/doc4.xml","form_type":"4"}},{"id":3798488,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-10-03T18:33:25.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":3040,"price":15.2583,"value":46385.232,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.76 to $15.755, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":2831,"source":{"system":"sec-edgar","filing":"0001209191-18-054090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118054090/doc4.xml","form_type":"4"}},{"id":3798487,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-10-03T18:33:25.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":5040,"price":0.99,"value":4989.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":5871,"source":{"system":"sec-edgar","filing":"0001209191-18-054090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118054090/doc4.xml","form_type":"4"}},{"id":3823271,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-06T17:08:33.000Z","date":"2018-09-04","kind":"exercise","acquired":false,"shares":5040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."}],"balance_after":15124,"derivative":{"exercise_price":0.99,"expiration_date":"2019-04-20","underlying":"Common Stock","underlying_shares":5040},"source":{"system":"sec-edgar","filing":"0001209191-18-049877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118049877/doc4.xml","form_type":"4"}},{"id":3823270,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-09-06T17:08:33.000Z","date":"2018-09-04","kind":"sale","acquired":false,"shares":5040,"price":17.9958,"value":90698.832,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.80 to $18.125, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":831,"source":{"system":"sec-edgar","filing":"0001209191-18-049877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118049877/doc4.xml","form_type":"4"}},{"id":3823269,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-09-06T17:08:33.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":5040,"price":0.99,"value":4989.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":5871,"source":{"system":"sec-edgar","filing":"0001209191-18-049877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118049877/doc4.xml","form_type":"4"}},{"id":3854913,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-02T17:48:16.000Z","date":"2018-08-01","kind":"exercise","acquired":false,"shares":5040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this stock option are fully vested."}],"balance_after":20164,"derivative":{"exercise_price":0.99,"expiration_date":"2019-04-20","underlying":"Common Stock","underlying_shares":5040},"source":{"system":"sec-edgar","filing":"0001209191-18-045042","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118045042/doc4.xml","form_type":"4"}},{"id":3854912,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-08-02T17:48:16.000Z","date":"2018-08-01","kind":"sale","acquired":false,"shares":980,"price":19.7638,"value":19368.524,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.70 to $19.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4."}],"balance_after":831,"source":{"system":"sec-edgar","filing":"0001209191-18-045042","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118045042/doc4.xml","form_type":"4"}},{"id":3854911,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-08-02T17:48:16.000Z","date":"2018-08-01","kind":"sale","acquired":false,"shares":4060,"price":19.4878,"value":79120.468,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.70 to $19.6750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":1811,"source":{"system":"sec-edgar","filing":"0001209191-18-045042","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118045042/doc4.xml","form_type":"4"}},{"id":3854910,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-08-02T17:48:16.000Z","date":"2018-08-01","kind":"exercise","acquired":true,"shares":5040,"price":0.99,"value":4989.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":5871,"source":{"system":"sec-edgar","filing":"0001209191-18-045042","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118045042/doc4.xml","form_type":"4"}},{"id":3874774,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-03T17:28:10.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":5040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."}],"balance_after":25204,"derivative":{"exercise_price":0.99,"expiration_date":"2019-04-20","underlying":"Common Stock","underlying_shares":5040},"source":{"system":"sec-edgar","filing":"0001209191-18-041240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118041240/doc4.xml","form_type":"4"}},{"id":3874773,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-03T17:28:10.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":7121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":7121},"source":{"system":"sec-edgar","filing":"0001209191-18-041240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118041240/doc4.xml","form_type":"4"}},{"id":3874772,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-07-03T17:28:10.000Z","date":"2018-07-02","kind":"sale","acquired":false,"shares":12161,"price":15.4892,"value":188364.1612,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.225 to $15.775, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":831,"source":{"system":"sec-edgar","filing":"0001209191-18-041240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118041240/doc4.xml","form_type":"4"}},{"id":3874771,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-07-03T17:28:10.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":5040,"price":0.99,"value":4989.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":12992,"source":{"system":"sec-edgar","filing":"0001209191-18-041240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118041240/doc4.xml","form_type":"4"}},{"id":3874770,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-07-03T17:28:10.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":7121,"price":1.65,"value":11749.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":7952,"source":{"system":"sec-edgar","filing":"0001209191-18-041240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118041240/doc4.xml","form_type":"4"}},{"id":3905133,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T17:41:52.000Z","date":"2018-06-01","kind":"exercise","acquired":false,"shares":5040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this stock option are fully vested."}],"balance_after":30244,"derivative":{"exercise_price":0.99,"expiration_date":"2019-04-20","underlying":"Common Stock","underlying_shares":5040},"source":{"system":"sec-edgar","filing":"0001209191-18-035868","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118035868/doc4.xml","form_type":"4"}},{"id":3905132,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T17:41:52.000Z","date":"2018-06-01","kind":"exercise","acquired":false,"shares":7121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this stock option are fully vested."}],"balance_after":7121,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":7121},"source":{"system":"sec-edgar","filing":"0001209191-18-035868","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118035868/doc4.xml","form_type":"4"}},{"id":3905131,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-06-05T17:41:52.000Z","date":"2018-06-01","kind":"sale","acquired":false,"shares":1100,"price":18.2864,"value":20115.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.25 to $18.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4."}],"balance_after":831,"source":{"system":"sec-edgar","filing":"0001209191-18-035868","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118035868/doc4.xml","form_type":"4"}},{"id":3905130,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-06-05T17:41:52.000Z","date":"2018-06-01","kind":"sale","acquired":false,"shares":11061,"price":17.8114,"value":197011.8954,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $18.2250, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":1931,"source":{"system":"sec-edgar","filing":"0001209191-18-035868","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118035868/doc4.xml","form_type":"4"}},{"id":3905129,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-06-05T17:41:52.000Z","date":"2018-06-01","kind":"exercise","acquired":true,"shares":5040,"price":0.99,"value":4989.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":12992,"source":{"system":"sec-edgar","filing":"0001209191-18-035868","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118035868/doc4.xml","form_type":"4"}},{"id":3905128,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-06-05T17:41:52.000Z","date":"2018-06-01","kind":"exercise","acquired":true,"shares":7121,"price":1.65,"value":11749.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":7952,"source":{"system":"sec-edgar","filing":"0001209191-18-035868","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118035868/doc4.xml","form_type":"4"}},{"id":3925698,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-18T17:57:47.000Z","date":"2018-05-16","kind":"exercise","acquired":false,"shares":7121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."}],"balance_after":14242,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":7121},"source":{"system":"sec-edgar","filing":"0001209191-18-031528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118031528/doc4.xml","form_type":"4"}},{"id":3925697,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-18T17:57:47.000Z","date":"2018-05-16","kind":"exercise","acquired":false,"shares":5040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this stock option are fully vested."}],"balance_after":35284,"derivative":{"exercise_price":0.99,"expiration_date":"2019-04-20","underlying":"Common Stock","underlying_shares":5040},"source":{"system":"sec-edgar","filing":"0001209191-18-031528","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118031528/doc4.xml","form_type":"4"}},{"id":3925696,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-05-18T17:57:47.000Z","date":"2018-05-16","kind":"sale","acquired":false,"shares":12161,"price":15.0282,"value":182757.9402,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.85 to $15.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":831,"source":{"system":"sec-edgar","filing":"0001209191-18-031528","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118031528/doc4.xml","form_type":"4"}},{"id":3925695,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-05-18T17:57:47.000Z","date":"2018-05-16","kind":"exercise","acquired":true,"shares":7121,"price":1.65,"value":11749.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":12992,"source":{"system":"sec-edgar","filing":"0001209191-18-031528","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118031528/doc4.xml","form_type":"4"}},{"id":3925694,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Common Stock","published_at":"2018-05-18T17:57:47.000Z","date":"2018-05-16","kind":"exercise","acquired":true,"shares":5040,"price":0.99,"value":4989.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":5871,"source":{"system":"sec-edgar","filing":"0001209191-18-031528","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118031528/doc4.xml","form_type":"4"}},{"id":4044059,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Managing Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-21T17:36:47.000Z","date":"2018-02-16","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2018 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":60000,"derivative":{"exercise_price":13.55,"expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-18-012041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919118012041/doc4.xml","form_type":"4"}},{"id":4128531,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"The shares subject to this option shall vest and become exer","published_at":"2017-12-18T18:30:57.000Z","date":"2017-12-14","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of December 14, 2017 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":50000,"derivative":{"exercise_price":10.7,"expiration_date":"2027-12-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-066207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117066207/doc4.xml","form_type":"4"}},{"id":4274478,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-22T18:12:08.000Z","date":"2017-06-20","kind":"exercise","acquired":false,"shares":585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this stock option are fully vested."}],"balance_after":40324,"derivative":{"exercise_price":0.99,"expiration_date":"2019-04-20","underlying":"Common Stock","underlying_shares":585},"source":{"system":"sec-edgar","filing":"0001209191-17-041449","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117041449/doc4.xml","form_type":"4"}},{"id":4274477,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2017-06-22T18:12:08.000Z","date":"2017-06-20","kind":"sale","acquired":false,"shares":585,"price":20,"value":11700.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2017."}],"balance_after":831,"source":{"system":"sec-edgar","filing":"0001209191-17-041449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117041449/doc4.xml","form_type":"4"}},{"id":4274476,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2017-06-22T18:12:08.000Z","date":"2017-06-20","kind":"exercise","acquired":true,"shares":585,"price":0.99,"value":579.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2017."}],"balance_after":1416,"source":{"system":"sec-edgar","filing":"0001209191-17-041449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117041449/doc4.xml","form_type":"4"}},{"id":4475225,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-01-31T17:25:39.000Z","date":"2017-01-27","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2017 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":85000,"derivative":{"exercise_price":20.4,"expiration_date":"2027-01-26","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-17-006430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919117006430/doc4.xml","form_type":"4"}},{"id":4533232,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-05T18:47:56.000Z","date":"2016-12-01","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this stock option are fully vested."}],"balance_after":21363,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-16-153491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116153491/doc4.xml","form_type":"4"}},{"id":4533231,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-12-05T18:47:56.000Z","date":"2016-12-01","kind":"sale","acquired":false,"shares":500,"price":23.62,"value":11810.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.20 to $23.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4"}],"balance_after":831,"source":{"system":"sec-edgar","filing":"0001209191-16-153491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116153491/doc4.xml","form_type":"4"}},{"id":4533230,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-12-05T18:47:56.000Z","date":"2016-12-01","kind":"sale","acquired":false,"shares":2500,"price":22.6072,"value":56518.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.20 to $23.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4"}],"balance_after":1331,"source":{"system":"sec-edgar","filing":"0001209191-16-153491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116153491/doc4.xml","form_type":"4"}},{"id":4533229,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-12-05T18:47:56.000Z","date":"2016-12-01","kind":"exercise","acquired":true,"shares":3000,"price":1.65,"value":4950.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 831 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on November 30, 2016."}],"balance_after":3831,"source":{"system":"sec-edgar","filing":"0001209191-16-153491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116153491/doc4.xml","form_type":"4"}},{"id":4567608,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-11-03T18:39:46.000Z","date":"2016-11-01","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this stock option are fully vested."}],"balance_after":24363,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-16-148271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116148271/doc4.xml","form_type":"4"}},{"id":4567607,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-11-03T18:39:46.000Z","date":"2016-11-01","kind":"sale","acquired":false,"shares":400,"price":24.875,"value":9950.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.80 to $24.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-16-148271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116148271/doc4.xml","form_type":"4"}},{"id":4567606,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-11-03T18:39:46.000Z","date":"2016-11-01","kind":"sale","acquired":false,"shares":2600,"price":24.2623,"value":63081.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.80 to $24.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4"}],"balance_after":400,"source":{"system":"sec-edgar","filing":"0001209191-16-148271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116148271/doc4.xml","form_type":"4"}},{"id":4567605,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-11-03T18:39:46.000Z","date":"2016-11-01","kind":"exercise","acquired":true,"shares":3000,"price":1.65,"value":4950.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-16-148271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116148271/doc4.xml","form_type":"4"}},{"id":4584273,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-05T19:02:54.000Z","date":"2016-10-03","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this stock option are fully vested."}],"balance_after":27363,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-16-145140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116145140/doc4.xml","form_type":"4"}},{"id":4584272,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-10-05T19:02:54.000Z","date":"2016-10-03","kind":"sale","acquired":false,"shares":702,"price":31.6218,"value":22198.5036,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.43 to\n$32.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote 4 to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-16-145140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116145140/doc4.xml","form_type":"4"}},{"id":4584271,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-10-05T19:02:54.000Z","date":"2016-10-03","kind":"sale","acquired":false,"shares":2298,"price":30.9906,"value":71216.3988,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.42 to\n$31.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in\nthis footnote 3 to this Form 4."}],"balance_after":702,"source":{"system":"sec-edgar","filing":"0001209191-16-145140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116145140/doc4.xml","form_type":"4"}},{"id":4584270,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-10-05T19:02:54.000Z","date":"2016-10-03","kind":"exercise","acquired":true,"shares":3000,"price":1.65,"value":4950.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-16-145140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116145140/doc4.xml","form_type":"4"}},{"id":4611009,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-06T18:34:24.000Z","date":"2016-09-01","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested."}],"balance_after":30363,"derivative":{"exercise_price":1.65,"expiration_date":"2018-07-22","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-16-140247","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116140247/doc4.xml","form_type":"4"}},{"id":4611008,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-09-06T18:34:24.000Z","date":"2016-09-01","kind":"sale","acquired":false,"shares":100,"price":33.1,"value":3310.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-16-140247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116140247/doc4.xml","form_type":"4"}},{"id":4611007,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-09-06T18:34:24.000Z","date":"2016-09-01","kind":"sale","acquired":false,"shares":2900,"price":32.4735,"value":94173.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $32.09 to $33.05, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0001209191-16-140247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116140247/doc4.xml","form_type":"4"}},{"id":4611006,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":69500,"kind":"person","name":"Smith Jeffrey T L","position":1,"cik":"0001604800","reported_name":"Smith Jeffrey T L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP Translational Medicine"}}],"security":"Common Stock","published_at":"2016-09-06T18:34:24.000Z","date":"2016-09-01","kind":"exercise","acquired":true,"shares":3000,"price":1.65,"value":4950.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2016."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-16-140247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423824/000120919116140247/doc4.xml","form_type":"4"}}]}